Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)

CONCLUSIONS: AT-MSCs could be safely administered to our pediatric cases with BoS post-allo-HSCT. Considering their advanced stage of disease, their sub-optimal functional capacity due to steroid-induced complications, and COVID-19 infection post-treatment, we believe that AT-MSC therapy can have possible efficacy in the management of pediatric BoS. The conduction of further studies with larger sample sizes and more frequent injections is prudent for further optimization of AT-MSC therapy against BoS. Trial registration Iranian Registry of Clinical Trials (IRCT), IRCT20201202049568N2. Registered 22 February 2021, https://en.irct.ir/trial/53143 .PMID:37726865 | PMC:PMC10510238 | DOI:10.1186/s13287-023-03498-y

Source: Cell Research - September 19, 2023 Category: Cytology Authors: Rashin Mohseni Pouya Mahdavi Sharif Maryam Behfar Mohammad Reza Modaresi Rohola Shirzadi Mahta Mardani Leila Jafari Fahimeh Jafari Zeynab Nikfetrat Amir Ali Hamidieh Source Type: research